Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/15/2013
Clinical Research Facility
mi
from
Richmond, VA
MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003 AM6)
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/15/2013
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
Study to Evaluate the Effect of BMS-791325 on the Pharmacokinetics of the CYP3A4 Probe Midazolam Administered Orally in Healthy Subjects
Status: Enrolling
Updated:  6/7/2013
Wcct Global, Llc
mi
from
Cypress, CA
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
Study to Evaluate the Effect of BMS-791325 on the Pharmacokinetics of the CYP3A4 Probe Midazolam Administered Orally in Healthy Subjects
Status: Enrolling
Updated: 6/7/2013
Wcct Global, Llc
mi
from
Cypress, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Los Angeles, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
San Diego, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
San Marcos, CA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
San Marcos, CA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
New Port Richey, FL
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Orlando, FL
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Tampa, FL
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
New Orleans, LA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Manhasset, NY
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Germantown, TN
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Dallas, TX
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Murray, UT
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Burlington, VT
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated:  6/27/2013
Clinical Research Facility
mi
from
Richmond, VA
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)
Status: Enrolling
Updated: 6/27/2013
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
Borland-Grooover Clinic
mi
from
Jacksonville, FL
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
Borland-Grooover Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
Venture Research Institute
mi
from
Miami, FL
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
Venture Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
Orlando Immunology Center
mi
from
Orlando, FL
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
Orlando Immunology Center
mi
from
Orlando, FL
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
MetroWest Medical Center
mi
from
Framingham, MA
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
MetroWest Medical Center
mi
from
Framingham, MA
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
UMASS Memorial Medical Center
mi
from
Worcester, MA
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
UMASS Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated:  7/9/2013
Cumberland Research Associates
mi
from
Fayetteville, NC
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: Enrolling
Updated: 7/9/2013
Cumberland Research Associates
mi
from
Fayetteville, NC
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated:  7/17/2013
Clinical Research Facility
mi
from
Fort Myers, FL
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated: 7/17/2013
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated:  7/17/2013
Clinical Research Facility
mi
from
San Antonio, TX
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status: Enrolling
Updated: 7/17/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Status: Enrolling
Updated:  7/23/2013
Indiana University School of Medicine - IUHealth-University Hospital
mi
from
Indianapolis, IN
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Status: Enrolling
Updated: 7/23/2013
Indiana University School of Medicine - IUHealth-University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  8/6/2013
University of Miami, Division of Clinical Pharmacology
mi
from
Miami, FL
To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 8/6/2013
University of Miami, Division of Clinical Pharmacology
mi
from
Miami, FL
Click here to add this to my saved trials
To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  8/6/2013
Orlando Clinical Research Center
mi
from
Orlando, FL
To Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 8/6/2013
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Mayo Clinic Hospital
mi
from
Phoenix, AZ
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
University of California Antiviral Research Center (AVRC)
mi
from
San Diego, CA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
University of California Antiviral Research Center (AVRC)
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Indiana University Medical Center
mi
from
Indianapolis, IN
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Tulane University Health Sciences Center
mi
from
New Orleans, LA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
National Institute of Allergy and Infectious Diseases
mi
from
Bethesda, MD
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
National Institute of Allergy and Infectious Diseases
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Henry Ford Hospital
mi
from
Detroit, MI
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Scientella, LLC
mi
from
Creve Coeur, MO
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Scientella, LLC
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Kansas City Gastroenterology & Hepatology
mi
from
Kansas City, MO
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Kansas City Gastroenterology & Hepatology
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Weill Medical College of Cornell University
mi
from
New York, NY
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
CRI Worldwide, LLC
mi
from
Philadelphia, PA
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
Baylor College of Medicine
mi
from
Houston, TX
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  8/8/2013
University of Utah
mi
from
Salt Lake City, UT
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 8/8/2013
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated:  8/8/2013
Axis Clinical Trials
mi
from
Los Angeles, CA
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated: 8/8/2013
Axis Clinical Trials
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated:  8/8/2013
Prism Research
mi
from
St. Paul, MN
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated: 8/8/2013
Prism Research
mi
from
St. Paul, MN
Click here to add this to my saved trials
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated:  8/8/2013
New Orleans Center for Clinical Research - Knoxville
mi
from
Knoxville, TN
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated: 8/8/2013
New Orleans Center for Clinical Research - Knoxville
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated:  8/8/2013
Alamo Medical Research
mi
from
San Antonio, TX
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Status: Enrolling
Updated: 8/8/2013
Alamo Medical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  9/24/2013
Mayo Clinic Hospital
mi
from
Phoenix, AZ
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 9/24/2013
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated:  9/24/2013
University of California Antiviral Research Center (AVRC)
mi
from
San Diego, CA
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Status: Enrolling
Updated: 9/24/2013
University of California Antiviral Research Center (AVRC)
mi
from
San Diego, CA
Click here to add this to my saved trials